2014
Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers
Adeniran AJ, Hui P. Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. Expert Review Of Endocrinology & Metabolism 2014, 9: 571-577. PMID: 30736195, DOI: 10.1586/17446651.2014.951635.Peer-Reviewed Original ResearchBRAF V600E mutationPapillary thyroid carcinomaThyroid carcinomaV600E mutationPAX8/PPARγ rearrangementsSubsequent core needle biopsyUndetermined significance/atypiaFine needle aspiration cytologyBRAF V600E mutation testingLow-stage diseaseCore needle biopsyRoutine clinical practiceAggressive tumor behaviorNeedle aspiration cytologyBRAF mutation testingFine-needle aspiration specimensUndetermined significance categoryIndeterminate fine-needle aspiration cytologyNeedle aspiration specimensPredictability of malignancyCommon genetic alterationsMutation testingRET/papillary thyroid carcinomaThyroid fine-needle aspiration specimensIndependent predictors
2012
BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation
Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML. BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation. Modern Pathology 2012, 26: 62-70. PMID: 22918165, DOI: 10.1038/modpathol.2012.152.Peer-Reviewed Original ResearchConceptsPapillary thyroid microcarcinomaThyroid microcarcinomaPapillary thyroid carcinomaFollicular variantThyroid carcinomaLateral cervical node metastasesOsteoclastic-type giant cellsCervical node metastasisInfiltrative tumor borderGroup of tumorsBRAF V600E mutationClassic nuclear featuresGenotype-phenotype correlationStromal calcificationLymphovascular invasionNode metastasisClinicopathologic featuresLymphocytic infiltrationAggressive featuresTumor sizeCystic changesPapillary microcarcinomaAbsence of mutationsHigh prevalenceMicrocarcinomaBRAF mutation testing in clinical practice
Ziai J, Hui P. BRAF mutation testing in clinical practice. Expert Review Of Molecular Diagnostics 2012, 12: 127-138. PMID: 22369373, DOI: 10.1586/erm.12.1.Peer-Reviewed Original ResearchConceptsHairy cell leukemiaBRAF mutation testingPapillary thyroid carcinomaMalignant melanomaThyroid carcinomaCell leukemiaClinical practiceCutaneous malignant melanomaSerine/threonine-protein kinase BRAFCurrent clinical practiceImportant biological markerMEK/ERKTreatment paradigmClinical trialsHigh prevalenceBRAF inhibitorsBRAF mutationsMutation testingPrecision cancer therapyTherapeutic guidanceMutant BRAFLethal diseaseBiological markersCancerHuman cancersPapillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct
Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 2012, 60: 1052-1059. PMID: 22335197, DOI: 10.1111/j.1365-2559.2011.04149.x.Peer-Reviewed Original Research